Kairos Pharma (KAPA) reports 19,084 RSU award to director

Rhea-AI Filing Summary

Kairos Pharma, Ltd. (KAPA) reported an insider equity award on a Form 4. Director Rahul Singhvi received 19,084 restricted stock units (RSUs) of common stock on 10/08/2025 under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. These 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date and were recorded at a price of $0.00, reflecting that this is an equity award, not an open-market purchase.

Following this grant, Singhvi beneficially owns 49,204 RSUs, all of which remain subject to vesting conditions and are reported as directly held. The filing is made by a single reporting person in the capacity of director, and it documents non-derivative equity compensation rather than any sale of shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Singhvi Rahul

Role Director

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	19,084	$0.00	--

Holdings After Transaction: COMMON STOCK — 49,204 shares (Direct)

Footnotes (1)

1. Represents 19,084 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. Consists of 49,204 RSUs which remain subject to vesting.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Singhvi Rahul

(Last) (First) (Middle)

C/O KAIROS PHARMA, LTD.

2355 WESTWOOD BLVD, #139

(Street)

LOS ANGELES CA 90064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kairos Pharma, LTD. [ KAPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	10/08/2025		A		19,084(1)	A	$0.00	49,204(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 19,084 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.

2. Consists of 49,204 RSUs which remain subject to vesting.

	/s/ Rahul Singhvi	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kairos Pharma (KAPA) disclose in this Form 4?

The filing reports that director Rahul Singhvi was granted 19,084 restricted stock units (RSUs) of Kairos Pharma, Ltd. common stock on 10/08/2025 under the companys 2023 Equity Incentive Plan.

What is the vesting schedule for the 19,084 Kairos Pharma RSUs granted?

The 19,084 RSUs granted to Rahul Singhvi are scheduled to vest in full on the first anniversary of the grant date, according to the disclosure.

How many Kairos Pharma RSUs does the reporting person own after the transaction?

After the reported grant, Rahul Singhvi beneficially owns 49,204 RSUs of Kairos Pharma, Ltd., and these RSUs remain subject to vesting conditions.

What was the price reported for the Kairos Pharma RSU grant?

The RSU grant was reported at a price of $0.00 per unit, reflecting that it is an equity compensation award rather than a market purchase.

What is the relationship of the reporting person to Kairos Pharma (KAPA)?

The reporting person, Rahul Singhvi, is identified in the filing as a Director of Kairos Pharma, Ltd. and not as a 10% owner.

Does this Kairos Pharma Form 4 involve derivative securities like options or warrants?

No. The reported transaction involves non-derivative securities in the form of RSUs. The table for derivative securities shows no entries.